CLL-115 First Interim Analysis of ALPINE Study: Results of a Phase 3 Randomized Study of Zanubrutinib vs Ibrutinib in Patients With Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Jennifer R. Brown(Dana-Farber Cancer Institute), Wojciech Jurczak(Jagiellonian University), Nicole Lamanna(Memorial Sloan Kettering Cancer Center), Lugui Qiu(Chinese Academy of Medical Sciences & Peking Union Medical College), Tommi Salmi(Düsseldorf University Hospital), Alessandra Ferrajoli(The University of Texas MD Anderson Cancer Center), Peter Ganly(European Bioinformatics Institute), Constantine S. Tam(The Alfred Hospital), Kenneth K. Wu(Illinois College), Robert Weinkove(Malaghan Institute of Medical Research), Keshu Zhou(Zhengzhou University), Mazyar Shadman(University of Washington), Jiřı́ Mayer(Masaryk University), Amanda Gillespie-Twardy(Düsseldorf University Hospital), William Novotny(Virginia Oncology Associates), Martin Šimkovič(Charles University), Barbara Eichhorst(University of Cologne), Maciej Kaźmierczak(Silesian University of Technology), Peter Hillmen(Leeds Teaching Hospitals NHS Trust), Susan O’Brien(University of California, Irvine)
Cited by 12
Related Papers
Genomic Classification and Prognosis in Acute Myeloid Leukemia
|New England Journal of Medicine|2016|4.4k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k